RVIDXIHVAACTPD-ADKRDUOOSA-N
C33H27F6N5O5 — CID 56968510
Data last refreshed: (MolForge compound catalog, from PubChem)
About RVIDXIHVAACTPD-ADKRDUOOSA-N
RVIDXIHVAACTPD-ADKRDUOOSA-N (PubChem CID 56968510) has the molecular formula C33H27F6N5O5 and a molecular weight of 687.60 g/mol. Its IUPAC name is 5-[3-[6-(azetidin-1-yl)-2-[[(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl]methyl]-3-pyridinyl]-4-methoxyphenyl]pyrazine-2-carboxylic acid.
Molecular Properties
| Compound Name | RVIDXIHVAACTPD-ADKRDUOOSA-N |
|---|---|
| PubChem CID | 56968510 |
| Molecular Formula | C33H27F6N5O5 |
| Molecular Weight | 687.60 g/mol |
| Exact Mass | 687.19 |
| IUPAC Name | 5-[3-[6-(azetidin-1-yl)-2-[[(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl]methyl]-3-pyridinyl]-4-methoxyphenyl]pyrazine-2-carboxylic acid |
| SMILES | COc1ccc(-c2cnc(C(=O)O)cn2)cc1-c1ccc(N2CCC2)nc1CN1C(=O)O[C@H](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@@H]1C |
| InChI | InChI=1S/C33H27F6N5O5/c1-17-29(19-10-20(32(34,35)36)13-21(11-19)33(37,38)39)49-31(47)44(17)16-26-22(5-7-28(42-26)43-8-3-9-43)23-12-18(4-6-27(23)48-2)24-14-41-25(15-40-24)30(45)46/h4-7,10-15,17,29H,3,8-9,16H2,1-2H3,(H,45,46)/t17-,29-/m0/s1 |
| InChIKey | RVIDXIHVAACTPD-ADKRDUOOSA-N |
| XLogP | 7.24 |
| TPSA | 117.98 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 49 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 687.60 |
| LogP ≤ 5 | 7.24 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 56968510 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.